Investor Relations

Corporate Profile

Fractyl Health is a clinical-stage metabolic therapeutics company focused on pioneering new approaches to treat obesity and T2D. Our Revita® and Rejuva® platform candidates are designed to target root causes of metabolic diseases and break the pattern of metabolic disease treatment from chronic management to potentially prevent and reverse metabolic disease. Fractyl Health is based in Burlington, Massachusetts.

Corporate Presentation

REMAIN-1 Midpoint Cohort One-Year Results

REVEAL-1 One-Year Results

Minimum 15 minutes delayed. Source: LSEG

News Releases

Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

Jul 15, 2026

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Jun 4, 2026

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

Jun 1, 2026

Events

REMAIN-1 Midpoint One-Year Results Conference Call

Jul 15, 2026 | 8:00 AM EDT

BofA Securities 2026 Health Care Conference

May 14, 2026 | 12:20 PM EDT

SEC Filings

Report of unscheduled material events or corporate event

Jul 15, 2026 | Form Type: 8-K

Jul 15, 2026

Statement of changes in beneficial ownership of securities

Jun 15, 2026 | Form Type: 4

Jun 15, 2026

Investor Relations Contacts

Brian Luque, Head of Investor Relations and Corporate Development

Email: ir@fractyl.com
Phone: 951.206.1200